|
Market Closed -
Nasdaq
00:00:00 02/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.830 USD | -2.41% |
|
-5.67% | -29.25% |
| 09-21 | X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to S&P Global BMI Index | CI |
| 09-08 | X4 Pharmaceuticals Reaches FDA Agreement on Revised Phase 3 Trial for Chronic Neutropenia Treatment | MT |
| Market Cap | 281M 249M 233M 212M 400M 27.01B 405M 2.82B 1.09B 13.76B 1.05B 1.03B 44.19B | P/E 2026 * |
-4.24x | P/E 2027 * | -3.91x |
|---|---|---|---|---|---|
| Enterprise Value | 190M 169M 158M 144M 270M 18.27B 274M 1.91B 738M 9.31B 713M 697M 29.89B | EV / Sales 2026 * |
11.9x | EV / Sales 2027 * | 7.49x |
| Free-Float |
91.56% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| XFOR | Delayed | |
CBOE
| XFOR | Real-time |
Last Transcript: X4 Pharmaceuticals, Inc.
| 1 day | -2.41% | ||
| 1 week | -5.67% | ||
| Current month | -2.41% | ||
| 1 month | -30.47% | ||
| 3 months | -30.72% | ||
| 6 months | -34.94% | ||
| Current year | -29.25% |
| 1 week | 2.81 |  | 3.06 |
| 1 month | 2.81 | | 4.13 |
| Current year | 2.81 | | 4.83 |
| 1 year | 2.8 | | 4.83 |
| 3 years | 1.35 | | 48 |
| 5 years | 1.35 | | 185.4 |
| 10 years | 1.35 | | 717.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Adam Craig
CEO | Chief Executive Officer | 60 | - |
David Kirske
DFI | Director of Finance/CFO | 71 | 12/08/2025 |
John Volpone
PSD | President | - | 12/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Wyzga
CHM | Chairman | 71 | 01/07/2018 |
Gary Bridger
BRD | Director/Board Member | 63 | 01/10/2018 |
Murray Stewart
BRD | Director/Board Member | 65 | 29/03/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/08/26 | Sell | Chief Operating Officer | -24,576 | 0.0261% | ||
| 12/08/26 | Sell | Chief Executive Officer | -47,436 | 0.0503% | ||
| 01/07/26 | Free | Director | 110,000 | 0.1166% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.41% | -5.67% | -21.82% | -91.35% | 288M | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,031B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 638B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 462B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 359B | |
| -0.03% | -3.96% | +23.63% | +39.35% | 335B | |
| -1.58% | -0.76% | +13.50% | +25.77% | 273B | |
| -2.02% | -2.97% | -3.25% | +8.38% | 253B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 228B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 185B | |
| Average | -1.51% | -1.99% | +22.54% | +42.47% | 376.41B | |
| Weighted average by Cap. | -1.25% | -1.89% | +30.51% | +69.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.98M 14.19M 13.27M 12.1M 22.77M 1.54B 23.08M 161M 62.16M 784M 60M 58.7M 2.52B | 11.56M 10.27M 9.6M 8.75M 16.47M 1.11B 16.7M 116M 44.97M 567M 43.4M 42.46M 1.82B |
| Net income | -86.82M -77.11M -72.11M -65.72M -124M -8.36B -125M -872M -338M -4.26B -326M -319M -13.67B | -104M -92.62M -86.62M -78.93M -149M -10.04B -151M -1.05B -406M -5.11B -392M -383M -16.42B |
| Net Debt | -90.8M -80.65M -75.42M -68.73M -129M -8.74B -131M -912M -353M -4.45B -341M -334M -14.3B | -194M -172M -161M -147M -276M -18.68B -280M -1.95B -755M -9.51B -728M -713M -30.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/10/26 | $2.830 | -2.41% | 501,492 |
| 30/09/26 | $2.900 | 0.00% | 1,764,647 |
| 29/09/26 | $2.900 | -3.81% | 1,710,138 |
| 28/09/26 | $3.015 | +0.17% | 838,399 |
| 25/09/26 | $3.010 | +0.33% | 1,856,553 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- XFOR Stock
Select your edition
All financial news and data tailored to specific country editions
